4-[(2-(pyrrolidin-1-yl)ethoxy)]benzenesulfonamide | 1375453-69-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(2-(pyrrolidin-1-yl)ethoxy)]benzenesulfonamide
• 英文别名: 4-(2-Pyrrolidin-1-ylethoxy)benzenesulfonamide
• CAS: 1375453-69-2
• 化学式: C₁₂H₁₈N₂O₃S
• mdl: MFCD23714707
• 分子量: 270.353
• InChiKey: OMLSKMGYOARVQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  81
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[(2-(pyrrolidin-1-yl)ethoxy)]benzenesulfonamide 、 环己基异氰酸酯 在 sodium hydroxide 作用下， 以 丙酮 为溶剂， 反应 4.17h， 以10%的产率得到1-cyclohexyl-3-[4-(2-pyrrolidin-1-ylethoxy)benzene]sulfonylurea
  参考文献：
  名称：

  Novel sulfonylurea derivatives as H3 receptor antagonists. Preliminary SAR studies

  摘要：

  The combination of antagonism at histamine H-3 receptor and the stimulation of insulin secretion have been proposed as an approach to new dual therapeutic agents for the treatment of type 2 diabetes mellitus associated with obesity. We have designed and synthesized a new series of non-imidazole derivatives, based on a basic amine ring connected through an alkyl spacer of variable length to a phenoxysulfonylurea moiety. These compounds were initially evaluated for histamine H-3 receptor binding affinities, suggesting that a propoxy chain linker between the amine and the core ring could be essential for optimal binding affinity. Compound 56, 1-(naphthalen-1-yl)-3-[(p-(3-pyrrolidin-1-ylpropoxy) benzene)]sulfonylurea exhibited the best H-3 antagonism affinity. However, since all these derivatives failed to block K-ATP channels, the link of these two related moieties should not be considered a good pharmacophore for obtaining new dual H-3 antagonists with insulinotropic activity, suggesting the necessity to propose a new chemical hybrid prototype. (C)2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.02.049
• 作为产物：
  描述：

  2-苯氧乙基溴 在 氯磺酸 、 氨 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 23.75h， 生成 4-[(2-(pyrrolidin-1-yl)ethoxy)]benzenesulfonamide
  参考文献：
  名称：

  Novel sulfonylurea derivatives as H3 receptor antagonists. Preliminary SAR studies

  摘要：

  The combination of antagonism at histamine H-3 receptor and the stimulation of insulin secretion have been proposed as an approach to new dual therapeutic agents for the treatment of type 2 diabetes mellitus associated with obesity. We have designed and synthesized a new series of non-imidazole derivatives, based on a basic amine ring connected through an alkyl spacer of variable length to a phenoxysulfonylurea moiety. These compounds were initially evaluated for histamine H-3 receptor binding affinities, suggesting that a propoxy chain linker between the amine and the core ring could be essential for optimal binding affinity. Compound 56, 1-(naphthalen-1-yl)-3-[(p-(3-pyrrolidin-1-ylpropoxy) benzene)]sulfonylurea exhibited the best H-3 antagonism affinity. However, since all these derivatives failed to block K-ATP channels, the link of these two related moieties should not be considered a good pharmacophore for obtaining new dual H-3 antagonists with insulinotropic activity, suggesting the necessity to propose a new chemical hybrid prototype. (C)2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.02.049

文献信息

• QUINAZOLINE DERIVATIVES AND USE THEREOF
  申请人：SUNTORY LIMITED

  公开号：EP0795548A1

  公开（公告）日：1997-09-17

  A chymase inhibitor containing as its effective ingredient a quinazoline derivative, or a pharmaceutically acceptable salt thereof, having the formula (1): and a pharmaceutical preparation for the prevention of cardiac and circulatory system diseases derived from abnormal exacerbation of Ang II production containing the same as its effective ingredient.

  一种糜蛋白酶抑制剂，其有效成分含有式（1）的喹唑啉衍生物或其药学上可接受的盐： 以及一种用于预防因血管紧张素 II 生成异常增加而引起的心脏和循环系统疾病的药物制剂，其有效成分也包含上述成分。
• Novel sulfonylurea derivatives as H3 receptor antagonists. Preliminary SAR studies
  作者：Javier Ceras、Nuria Cirauqui、Silvia Pérez-Silanes、Ignacio Aldana、Antonio Monge、Silvia Galiano

  DOI：10.1016/j.ejmech.2012.02.049

  日期：2012.6

  The combination of antagonism at histamine H-3 receptor and the stimulation of insulin secretion have been proposed as an approach to new dual therapeutic agents for the treatment of type 2 diabetes mellitus associated with obesity. We have designed and synthesized a new series of non-imidazole derivatives, based on a basic amine ring connected through an alkyl spacer of variable length to a phenoxysulfonylurea moiety. These compounds were initially evaluated for histamine H-3 receptor binding affinities, suggesting that a propoxy chain linker between the amine and the core ring could be essential for optimal binding affinity. Compound 56, 1-(naphthalen-1-yl)-3-[(p-(3-pyrrolidin-1-ylpropoxy) benzene)]sulfonylurea exhibited the best H-3 antagonism affinity. However, since all these derivatives failed to block K-ATP channels, the link of these two related moieties should not be considered a good pharmacophore for obtaining new dual H-3 antagonists with insulinotropic activity, suggesting the necessity to propose a new chemical hybrid prototype. (C)2012 Elsevier Masson SAS. All rights reserved.